Teva Pharmaceuticals USA, Inc. v. Sandoz, Inc.
| Teva Pharmaceuticals USA, Inc. v. Sandoz, Inc. | |
|---|---|
| Argued October 15, 2014 Decided January 20, 2015 | |
| Full case name | Teva Pharmaceuticals USA, Inc. v. Sandoz, Inc. |
| Docket no. | 13-854 |
| Citations | 574 U.S. 318 (more) |
| Case history | |
| Prior | 810 F. Supp. 2d 578 (S.D.N.Y. 2011); 876 F. Supp. 2d 295 (S.D.N.Y. 2012); affirmed in part, reversed in part, and remanded, 723 F.3d 1363 (Fed. Cir. 2013); stay denied, 572 U.S. 1301 (2014); cert. granted, 572 U.S. 1033 (2014) |
| Subsequent | On remand, 789 F.3d 1335 (Fed. Cir. 2015) |
| Holding | |
| When reviewing a district court’s resolution of subsidiary factual matters made in the course of its construction of a patent claim, the Federal Circuit must apply a "clear error," not a de novo, standard of review. | |
| Court membership | |
| |
| Case opinions | |
| Majority | Breyer, joined by Roberts, Scalia, Kennedy, Ginsburg, Sotomayor, Kagan |
| Dissent | Thomas, joined by Alito |
| Laws applied | |
| F.R.C.P. 52(a)(6) | |
Teva Pharmaceuticals USA, Inc. v. Sandoz, Inc., 574 U.S. 318 (2015), is a patent case of the Supreme Court of the United States regarding the Copaxone patent. The Court held that, when reviewing a district court’s resolution of subsidiary factual matters made in the course of its construction of a patent claim, the Federal Circuit must apply a "clear error," not a de novo, standard of review.